News | Molecular Imaging | March 02, 2017

Gamma Medica Expands Into European Breast Imaging Market

Partnership with medical supplies distributor enables women in the United Kingdom, Ireland and Channel Islands access to LumaGEM Molecular Breast Imaging for secondary breast cancer screening

Gamma Medica, European breast imaging market, LumaGem MBI, molecular breast imaging, Hospital Services Limited

March 2, 2017 — Gamma Medica announced it has partnered with Hospital Services Limited (HSL), a Dublin, Ireland-based established medical device company that distributes, installs and services radiology capital equipment and medical devices. This partnership will provide women with dense breast tissue access to Gamma Medica’s LumaGEM Molecular Breast Imaging (MBI) system in the United Kingdom, Ireland and the Channel Islands.

Women are eligible for the United Kingdom’s National Health Service (NHS) breast screening program at age 50-79 years, with women being invited to be screened every three years. Similarly in Ireland, women 50-69 years old are eligible for breast screenings every two years. Dense breast tissue not only increases the risk of developing breast cancer, but decreases the visibility of a cancer on conventional mammograms and other forms of anatomical imaging devices. Dense breast tissue and cancer both appear white on mammograms, making it difficult to distinguish between the two. This may lead to false negatives, unwarranted biopsies or delayed diagnoses.

Ideal for dense breast tissue, MBI significantly improves early detection of breast cancer in women with dense breast tissue. The technology has proven to be as effective as a secondary screening method compared to ultrasound or magnetic resonance imaging (MRI), with far fewer false positives. Peer-reviewed clinical research reports the use of LumaGEM MBI reduces the need for tissue biopsies by 50 percent compared to other modalities. MBI is also more comfortable and better tolerated by most patients than conventional mammography or MRI.

A retrospective study, which complemented earlier published prospective clinical research, was published in the American Journal of Roentgenologys August 2016 issue. This retrospective study monitored over 1,700 women with dense breast tissue over a three-year period. The study confirmed LumaGEM’s additional cancer detection rate of 7.7 cancers per 1,000, an increase from three cancers per 1,000 with mammography alone. The study also concluded that of the additional breast cancers found, approximately 85 percent were invasive and node negative, indicating they were detected at an early stage and therefore presented the patient with the likelihood of a better prognosis.

For more information: www.gammamedica.com

Related Content

Siemens Healthineers Introduces Mammomat Revelation Mammography System for Improved Biopsy Workflow
Technology | Mammography | December 11, 2017
Siemens Healthineers unveiled the new Mammomat Revelation premium mammography platform at the 2017 Radiological Society...
Breast Cancer Screening Performance Impacted by Mean Mammographic Compression Pressure
News | Mammography | December 08, 2017
Dutch researchers demonstrated a strong relationship between compression pressure in mammography and breast cancer...
Sponsored Content | Videos | Mammography | December 06, 2017
Martin Yaffe, Ph.D., FAAPM, senior scientist, physical sciences/imaging research, Sunnybrook Health Sciences Centre,
Ikonopedia and Konica Minolta Showcase Integrated Breast Imaging Workflow and Reporting at RSNA
News | Breast Imaging | December 05, 2017
Ikonopedia and Konica Minolta Healthcare Americas Inc. showcased integrated breast imaging workflow and reporting at...
Sponsored Content | Videos | Breast Imaging | December 05, 2017
Stamatia Destounis, M.D., FACR, associate professor, University of Rochester School of Medicine, attending radiologis
Numerous Studies Highlight Importance of Quantitative Breast Imaging Analysis at RSNA 2017
News | Breast Density | November 30, 2017
The importance of quantitative analysis in breast imaging was the focus of numerous abstracts accepted for presentation...
Hologic Receives FDA 510(k) Clearance of Quantra 2.2 Breast Density Assessment Software
Technology | Breast Density | November 28, 2017
Hologic Inc. announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its...
Eizo RadiForce RX560 Monitor Receives FDA 510(k) for Tomosynthesis and Digital Mammography
Technology | November 20, 2017
Eizo Corp. announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for breast tomosynthesis...
Biop Medical Launches Cervical Cancer Diagnosis Technology at MEDICA 2017

Biop Medical cervical cancer detection system

Technology | Women's Health | November 13, 2017
November 13, 2017 — Biop Medical announced it will present its point-of-care...
Overlay Init